Biopharmaceutical leader AbbVie has announced that the European Commission (EC) has formally granted marketing authorization expanding the indication for its... Read more
Tag: #Global Trends
US FDA declines to approve Achieve Life Sciences’ smoking-cessation drug over third-party manufacturing deficits
The U.S. Food and Drug Administration (FDA) has declined to approve Achieve Life Sciences' experimental drug engineered to treat adult... Read more
Pfizer’s experimental antibody-drug conjugate misses primary endpoint in late-stage lung cancer trial
Global pharmaceutical giant Pfizer Inc. announced that a key experimental oncology drug acquired through its high-premium $43,000 million buyout of... Read more
Shopify set to ban all vape products from its e-commerce platform under intense U.S. regulatory pressure
Ottawa-based e-commerce infrastructure giant Shopify Inc. is poised to ban all vaporizers and e-cigarettes (vapes) from its web hosting and... Read more
Global oncological milestone: China approves world’s first solid tumor-targeted CAR-T cell therapy
China’s National Medical Products Administration (NMPA) has executed a series of historic regulatory clearances, spearheaded by the landmark global approval... Read more
SK pharmteco partners with OTXL to accelerate clinical timelines for rare disease therapeutics
Global CDMO giant SK pharmteco has finalized a definitive collaborative agreement with the Orphan Therapeutics Accelerator (OTXL)—a non-profit biotechnology organization... Read more
Neurizon and Elanco ink long-term supply agreement for human-grade Monepantel to anchor ALS clinical pipeline
Biopharmaceutical innovator Neurizon Therapeutics has formalized a strategic, long-term supply agreement with Elanco Animal Health to secure comprehensive access to... Read more
Lupin launches generic Azilsartan Medoxomil tablets in the US with 180-day market exclusivity
Global pharmaceutical enterprise Lupin Limited has officially announced the commercial launch of Azilsartan Medoxomil Tablets in 40 mg and 80... Read more
FDA expands indication for Merck’s Capvaxive to include high-risk pediatric populations aged 2 to 17
The U.S. Food and Drug Administration (FDA) has granted an expanded indication for Merck & Co.’s 21-valent pneumococcal conjugate vaccine,... Read more








